

authority is contingent on Respondent being a practitioner with a valid DEA registration, *see* 21 U.S.C. 823(g)(2)(A); 21 CFR 1301.28(a), I will revoke his DATA-Waiver authority as well.

Order

Pursuant to the authority vested in me by 21 U.S.C. 823(f) and 824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of Registration No. BZ5641419 and DATA-Waiver Identification Number XZ5641419, issued to Witold Marek Zajewski, M.D., be, and they hereby are, revoked. I further order that any pending application of Witold Marek Zajewski to renew or modify the above registration, or any pending application of Witold Marek Zajewski for any other

registration in the State of Illinois, be, and it hereby is, denied. This Order is effective immediately.⁴

Dated: April 4, 2018.
Robert W. Patterson,
Acting Administrator.
 [FR Doc. 2018-07454 Filed 4-10-18; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Importer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of various classes of schedule I or II controlled substances.

SUPPLEMENTARY INFORMATION:

The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

Company	FR docket	Published
Sharp (Bethlehem), LLC	83 FR 539	January 4, 2018.
Catalent Pharma Solutions, LLC	83 FR 2215	January 16, 2018.
Janssen Pharmaceuticals, Inc	83 FR 2214	January 16, 2018.
Mylan Pharmaceuticals, Inc	83 FR 5809	February 9, 2018.
Meridian Medical Technologies, Inc	83 FR 5810	February 9, 2018.
Noramco, Inc	83 FR 5810	February 9, 2018.
Johnson Matthey, Inc	83 FR 5811	February 9, 2018.
Mylan Technologies, Inc	83 FR 5811	February 9, 2018.
Mylan Pharmaceuticals, Inc	83 FR 8107	February 23, 2018.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance

with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed companies.

Dated: April 4, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
 [FR Doc. 2018-07444 Filed 4-10-18; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of various classes of schedule I and II controlled substances.

SUPPLEMENTARY INFORMATION:

The companies listed below applied to be registered as bulk manufacturers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices.

Company	FR docket	Published
Nanosyn, Inc	82 FR 56993	December 1, 2017.
Janssen Pharmaceutical, Inc	82 FR 58027	December 8, 2017.
Cambrex High Point, Inc	82 FR 61795	December 29, 2017.
AMPAC Fine Chemicals LLC	82 FR 61795	December 29, 2017.
Organix, Inc	83 FR 150	January 2, 2018.
Johnson Matthey Inc	83 FR 2215	January 16, 2018.
Chemtos, LLC	83 FR 2671	January 18, 2018.
Alcami Wisconsin Corporation	83 FR 2675	January 18, 2018.

⁴ For the same reasons which led the IDFPFR to revoke Respondent's controlled substance license, I

conclude that the public interest necessitates that

this Order be effective immediately. 21 CFR 1316.67.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of these registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company's maintenance of effective controls against diversion by inspecting and testing each company's physical security systems, verifying each company's compliance with state and local laws, and reviewing each company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies.

Dated: April 3, 2018.

Susan A. Gibson,

Deputy Assistant Administrator.

[FR Doc. 2018-07455 Filed 4-10-18; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

**Importer of Controlled Substances
Application: Almac Clinical Services
Incorp (ACSI)**

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before May 11, 2018. Such persons may also file a written request for a hearing on the application on or before May 11, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on March 7, 2018, Almac Clinical Services Incorp (ACSI) 25 Fretz Road, Souderton, PA 18964 applied to be registered as an importer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Oxycodone	9143	II
Hydromorphone	9150	II
Morphine	9300	II
Tapentadol	9780	II
Fentanyl	9801	II

The company plans to import the listed controlled substances in dosage form to conduct clinical trials.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under to 21 U.S.C. 952 (a)(2).

Authorization will not extend to the import of FDA approved or non-approved finished dosage forms for commercial sale.

Dated: April 3, 2018

Susan A. Gibson,

Deputy Assistant Administrator.

[FR Doc. 2018-07441 Filed 4-10-18; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

[OMB Number 1121-0111]

**Agency Information Collection
Activities: Proposed eCollection
eComments Requested; Revision of a
Currently Approved Collection;
Comments Requested: National Crime
Victimization Survey (NCVS)**

AGENCY: Bureau of Justice Statistics, Department of Justice.

ACTION: 30-day notice.

SUMMARY: The Department of Justice (DOJ), Office of Justice Programs, Bureau of Justice Statistics, will be submitting a request to the Office of Management and Budget (OMB) for review and approval of a revision to the National Crime Victimization Survey information collection in accordance with the Paperwork Reduction Act of 1995. The proposed information collection, which is currently under OMB review, was previously published in the **Federal Register** on Monday, March 19, 2018, allowing a 30-day comment period. The requested revision impacts the minimum age at which respondents will be administered questions on their sexual orientation and gender identity, raising the minimum age from 16 to 18. This revision, which will be implemented within 6 months of OMB approval, will not impact the burden hours associated with the previous 30-day request.

DATES: Comments are encouraged and will be accepted for 30 days until May 11, 2018.

FOR FURTHER INFORMATION CONTACT:

If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Jennifer Truman, Statistician, Bureau of Justice Statistics, 810 Seventh Street NW, Washington, DC 20531 (email: Jennifer.Truman@ojp.usdoj.gov; telephone: 202-514-5083).

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

- Evaluate the impact of the change on the functioning of the Bureau of Justice Statistics;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information,